CuraGen Report issue

For profit Phase 2
Founded: Branford CT United States (1991)
Status: Acquired by Celldex Therapeutics (2009)

Organization Overview

First Clinical Trial
2005
NCT00104065
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CuraGen Corporation

Active Ingredients

Drugs in Phase 2 Trials (2)

glembatumumab vedotin (2 trials)

velafermin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Melanoma (Phase 2)

Mucositis (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2